Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK) header
Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK) profile picture

PROs (Lung NETs) Neuroendocrine Cancer UK Patient Support. INCA Research Committee Member @TheChristieNHS - Ask: - if not, why not?

Cheshire, UK
Joined March 2017
Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)Photo by Kate πŸ’™ #LetsTalkAboutNETs (@KateNCUK)
Delighted to represent the patient voice at this week’s Broncho-Pulmonary Education Event with Profs Mansoor ⁦@TheChristieNHS⁩ and Prof Evison ⁦@MFTnhs⁩ - key message: we must do more to standardise UK care and improve outcomes for this group.
1
1
98
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Were you looking for an excellent review on neuroendocrine neoplasm pathology focusing on the challenges of biopsy diagnoses written by true experts in the field? Worry not, I got you... link.springer.com/article/10…
2
11
40
2,185
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Thanks to @ncukcharity & all the amazing volunteers for all they do to increase awareness & support for patients with NEN & to the brilliant nursing team & all medical staff @TheChristie for all that they do #NETCancerday
Fantastic support from the Neuroendocrine Cancer team @TheChristieNHS today for World Neuroendocrine Cancer Awareness Day. Tell Someone. Make it visible. #NETCancerDay @MGMcNamara
1
1
77
Fantastic support from the Neuroendocrine Cancer team @TheChristieNHS today for World Neuroendocrine Cancer Awareness Day. Tell Someone. Make it visible. #NETCancerDay @MGMcNamara
1
3
144
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Thanks for raising awareness, Dr. Rocha! But why in the world does the SSO persist with the carcinoid cancer nonsense, literally cancer-like cancer? They are 26 years behind the times, and surgeons are notorious in the patient community for pooh-poohing NENs as "benign carcinoids". Not you, of course, but the SSO could be helping instead of hurting us. πŸ¦“
1
2
76
Kate πŸ’™ #LetsTalkAboutNETs retweeted
November marks Lung Cancer Awareness Month. For BTOG, improving outcomes for people affected by lung cancer starts with supporting the healthcare professionals who care for them. Throughout the month, we’ll continue to champion education, collaboration, research and the exchange of ideas across the thoracic oncology community – helping to ensure that patients have equitable access to optimal care. Together, we can keep driving progress in lung cancer care and contribute to achieving survival rates equal to the best in the world. #LungCancerAwarenessMonth #LungCancer #ThoracicOncology #BTOG
1
4
10
319
Kate πŸ’™ #LetsTalkAboutNETs retweeted
🧰 New tool: CRISIS-NET is live Expert consensus recommendations for carcinoid crisis πŸ’» Web-app: searchable with evidence summaries 🀝 Patient & care partner version with @NCFCancer πŸ‘€ Look at it πŸ”– Bookmark it πŸ“²Take it to the OR torontonets.github.io/carcin…
11
1
24
1,419
Kate πŸ’™ #LetsTalkAboutNETs retweeted
I know that @OncoThor has already posted this important NEN practice survey but as a pushy pt and advocate, I will "helpfully" tag @PamelaKunzMD , @JaydiDelRivero , @ChandrikhaC , @UGrewalMD , @AmanChauhanMD , @DianeReidyLagun , and @sonbol_bassam πŸ˜ŽπŸ¦“
2
3
5
233
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Replying to @OncoThor
Couldn't agree more. Here in the UK molecular testing is routinely denied for LNETs. We are told one never finds actionable mutations in LNETs.
1
1
2
54
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Thanks for bringing that up, Angela! I was hoping to have time to chat with @Alej_GarciaMD a little more at ESMO but I sent an email blast to the NET community and @UGrewalMD has been raising awareness too. So if you are a healthcare professional taking care of patients with NETs, please consider completing this short survey which is easy to do. It will provide valuable information.
Just competed the questionnaire Thanks @Alej_GarciaMD for putting this together - few practical questions on what we do in our daily practice @OncoThor shall we do a small push in the USA for a few more answers so we have a nice 🌎 picture? πŸ˜‰ @GrupoGetne @ENETS_ORG @NANETS1
5
12
1,180
Kate πŸ’™ #LetsTalkAboutNETs retweeted
If you are a patient with a NET or a family member or a friend or just interested NET, please check this website out.
I'm pleased to announce the launch of NENfolk.org, a patient educational site focused on neuroendocrine neoplasmsΒ (NENs) and radiotheranostics. NENfolk aims to help patients and caregivers find credible content from reputable organizations, and in the formats that fit how they want to learn. Please check it out!
1
6
18
1,309
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Standard vs. reduced dose of everolimus for patients with advanced NETs...? A retrospective study of 170 patients from Mayo Clinic and University Hospitals in Cleveland. @sonbol_bassam @Faresjamall @PatrickMcGarrah and others not found on X. Key findings: -- Patients in the reduced-dose cohort were older, with worse PS and more heavily pretreated -- Median OS was shorter in the reduced dose cohort, 43.7 vs. 81.5 months (p=0.02) -- After multivariate adjustment, the difference was no longer statistically significant -- Similarly, the observed difference in PFS (7 vs. 12.4 months), was no longer significant after adjusting -- Almost half of the full-dose starters needed dose reduction Lower doses may be reasonable in patients expected to have poor tolerance but cannot be routinely recommended. A prospective trial (NCT06472388) is ongoing, led by @RachelRiechelm2 onlinelibrary.wiley.com/doi/…
6
1
31
1,804
Kate πŸ’™ #LetsTalkAboutNETs retweeted
This is a good paper from @DrDavidLChan and team in Sydney. Oligodiscordant (my new fave imaging word) NETs are very real, not uncommon at all, especially lung NETs but also GEPNETs. Radioligand therapy may be of help but of note, the outcomes (OS and PFS) do seem inferior to what has been seen in RCTs previously published (NETTER 1 and 2, COMPETE). If the non-avid component(s) can also be treated effectively, (e.g. embolotherapy, RT, resection...), RLT may not be a bad option. link.springer.com/article/10…
8
23
1,404
Excellent presentation on Liver Transplantation for NETs by @HalletJulie at @ENETS_ORG webinar today - thank you. Interesting discussion on exactly what is now considered β€˜targetable disease’ when extra-hepatic. Sadly, no mention of lung NET primaries again by whole panel.
1
81
Kate πŸ’™ #LetsTalkAboutNETs retweeted
All of us who see patients with rare cancers (which is almost all my practice now...) know that without expert pathologists, we are blind, trying to navigate uncharted waters in the dark without a compass or GPS... Pathologists, just like the rest of us, are not infallible and sometimes get things wrong (we all do...). This very interesting study looks at the challenges in pathological diagnosis of neuroendocrine neoplasms (NENs) and the experience of ENDOCAN-TENpath, the French national expert network for NEN pathology which has monthly virtual "third-reading" sessions for collegial review of difficult cases (what a brilliant concept!). Not surprisingly, diagnoses change after such a review, often with major therapeutic consequences. Here are some of their findings: -- Of 3239 cases received by ENDOCAN-TENpath, 126 (3.9%) were submitted to third-reading by 22 of 33 network pathologists -- Diagnostic difficulties fell into four categories: high-grade NEN classification (33.3%), mixed neuroendocrine/non-neuroendocrine neoplasm diagnosis (36.5%), incomplete neuroendocrine phenotypes (23.0%), and unfamiliar entities (7.1%) -- Consensus or majority diagnosis was reached in 102 cases (81%). Unresolved cases were due to lack of consensus (n = 13) or insufficient material (n = 10) -- Critically, the process yielded decisions with major therapeutic consequences: 20/46 presumed NENs were reclassified as non-neuroendocrine malignancies and 5/25 presumed adenocarcinomas as NENs, fundamentally altering treatment strategy. -- 32/42 ambiguous high-grade NENs were definitively classified as tumor or carcinoma, directly determining first-line chemotherapy regimen. This illustrates the need for expert centers with expert pathologists who are willing to collaborate. I have already seen a few similar cases this year, including a patient treated with chemo for presumed poorly diff duodenal adenocarcinoma which turned out to be lipid-rich grade 2 well diff NET... A very challenging case able to trick even the best pathologists. And naturally, I must tag @IHC_guy on this post... sciencedirect.com/science/ar…
5
9
36
1,696
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Time for a prospective trial of DLL3-targeting BiTEs in lung NETs. In this small study of 11 patients with mostly what will soon be called G3 lung NETs (finally!), all DLL3+, tarlatamab resulted in ORR of 73% and stability in others. CRS was common but mostly grade 2 or lower. I am ready for a trial and I know many of the patients I see are as well... sciencedirect.com/science/ar…
2
16
36
1,608
Kate πŸ’™ #LetsTalkAboutNETs retweeted
The classification of lung NETs is moving closer to the one for NETs below the diaphragm. Well diff grade 3 NETs (G3 NETs) of the lung will be introduced and they really seem to be a thing... (see link in comments with the IASLC updates). In this small study (small in terms of G3 lung NETs - all p53 wt, Rb1 retained), they seem to have a different prognosis. As always, more work is needed including on optimal therapy and more... sciencedirect.com/science/ar…
1
11
1
27
1,880
Kate πŸ’™ #LetsTalkAboutNETs retweeted
This is the best paper you will read on nuclear imaging in patients with NETs this summer. Trust me! onlinelibrary.wiley.com/doi/… @ENETS_ORG @deroose_c @HansHofland1 @DrAngelaLamarca This is the table I always needed for myself and for teaching...
3
15
42
2,893
Kate πŸ’™ #LetsTalkAboutNETs retweeted
Well done to all authors including @UGrewalMD @OncoThor tackling emerging therapeutic strategies in NENs. More article types soon to be accepted in @ASCO Educational book @ENETS_ORG @ncukcharity
Elated to share our latest in @ASCO Educational Book on the evolving role of personalized therapies in Neuroendocrine Neoplasms. πŸ”— ascopubs.org/doi/10.1200/EDB… Grateful to Drs Simron Singh, Jen Chan and @OncoThor for the opportunity to be a part of this tour de force. The book chapter discusses biomarker-driven advances in radioligand therapy, targeted therapies, and emerging novel agents across NEN spectrum. @SShaheenMD
1
5
13
1,249